The PneumRx® Endobronchial Coil System

PneumRx® Coils are an investigational device in the United States and are under evaluation for the treatment of severe emphysema.


Emphysema and RENEW

Emphysema, a form of COPD, is characterized by alveolar destruction, loss of the lung’s natural elastic recoil. This leads to air trapping and hyperinflation of the lungs, making breathing difficult.

Traditional treatment options include smoking cessation, pharmacological drug therapy (inhaled steroids, bronchodilators and antibiotics), supplemental oxygen and pulmonary rehabilitation (breathing exercises). As emphysema is a progressive disease, eventually these standard treatments will no longer relieve the patient’s symptoms.

BTG’s flagship Interventional Pulmonology product, the PneumRx® Coils are minimally invasive implants intended to improve exercise capacity, lung function and quality of life in patients with both heterogeneous and/or homogeneous severe emphysema.

In October of 2014, enrollment for the 315-subject Coil pivotal trial at 26 sites in the United States, Canada and Europe was completed. RENEW is a randomized controlled study with a primary endpoint of improvement in 6 Minute Walk Test from baseline to 12 months, comparing PneumRx Coil treatment to standard of care.


The PneumRx™ Endobronchial Coil System is an investigational device in the United States, limited by United States law to investigational use. It is not available for commercial sale in the United States.